1. Is there any relationship between the exposure to mycophenolic acid and the clinical status in children with lupus?
- Author
-
C. Jurado, M Fischbac, Bruno Ranchin, Etienne Bérard, Stéphane Decramer, Franck Saint-Marcoux, Brigitte Bader-Meunier, Pharmacologie des Immunosuppresseurs et de la Transplantation (PIST), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Pharmacologie, toxicologie et pharmacovigilance [CHU Limoges], CHU Limoges, Service d'immunologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de néphrologie pédiatrique, CHU Lyon, Service de Pédiatrie - Néphrologie, Médecine interne, Hypertension, CHU Toulouse [Toulouse]-Hôpital des Enfants, CHU Toulouse [Toulouse], Service de pédiatrie, CHU Strasbourg, Service de Néphrologie Pédiatrique, Centre Hospitalier Universitaire de Nice (CHU Nice)-Fondation LENVAL-Hopital pour Enfants, BMC, Ed., and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
- Subjects
medicine.medical_specialty ,Pediatrics ,lcsh:Diseases of the musculoskeletal system ,Logistic regression ,Gastroenterology ,Mycophenolic acid ,[SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics ,Rheumatology ,Pharmacokinetics ,Internal medicine ,Area under curve ,medicine ,Immunology and Allergy ,Pediatrics, Perinatology, and Child Health ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics ,Systemic lupus erythematosus ,medicine.diagnostic_test ,business.industry ,lcsh:RJ1-570 ,lcsh:Pediatrics ,medicine.disease ,3. Good health ,[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,Therapeutic drug monitoring ,Poster Presentation ,Pediatrics, Perinatology and Child Health ,lcsh:RC925-935 ,business ,medicine.drug - Abstract
Methods We launched a non-interventional study with analysis of clinical, biological and pharmacokinetic information. Full-PK profiles of MPA were modelled using an iterative two-stage approach (1). The clinical status was defined by the SLEDAI, the SLE being considered active for a score ≥6. Relationships between MPA through concentrations (C0), AUC (Area Under Curve) or AUC/ dose values, and the disease’s activity were studied using logistic regression analysis.
- Published
- 2011